Geron Corporation

(GERN) Trade

By |

Profile

Geron Corp is a clinical stage biopharmaceutical company. Its focus is the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imelstat is expected to directly obstruct malignant-cell proliferation. The company has an exclusive collaboration and license agreement with Janssen Biotech to develop and commercialize imetelstat worldwide for oncology and other human therapeutic uses.

Contact Information

Website: www.geron.com
Email: investor@geron.com
Main Phone: +1 650 473-7700
Address: 149 Commonwealth Drive
Address 2: Suite 2070
State: CA
City / Town: Menlo Park
Country: USA
Postal Code: 94025

Issuer Information

Exchange: NGS
CEO: John A. Scarlett
Employees: 18
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

Geron Corp is a clinical stage biopharmaceutical company. Its focus is the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imelstat is expected to directly obstruct malignant-cell proliferation. The company has an exclusive collaboration and license agreement with Janssen Biotech to develop and commercialize imetelstat worldwide for oncology and other human therapeutic uses.

Contact Information

Website: www.geron.com
Email: investor@geron.com
Main Phone: +1 650 473-7700
Address: 149 Commonwealth Drive
Address 2: Suite 2070
State: CA
City / Town: Menlo Park
Country: USA
Postal Code: 94025

Issuer Information

Exchange: NGS
CEO: John A. Scarlett
Employees: 18
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 1.48 $ -0.05 (-3.27%)
Last Price 1.48 Change $ -0.05 Change % -3.27 Tick N/A
Bid 1.49 Bid Size 200.00 Ask 1.62 Ask Size 200.00
Open 1.52 High 1.55 Low 1.48 Prev Close 1.53
Last Trade Volume 1.8 mi 52 Wk Hi 6.99 52 Wk Low 0.95
Market Cap 276 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 186,516,047.00 EPS (TTM) -0.16 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 9
Number of Buys 0 9
Number of Sells 0 0
Net Activity 0 54583
Last 10 Buys Shares
Daniel M. Bradbury 1,000
John A. Scarlett 1,000
John A. Scarlett 1,000
Thomas D. Kiley 1,000
Thomas D. Kiley 1,000
Last 10 Sell Shares
Melissa A. Kelly Behrs 1,000
Olivia Bloom 1,000
Thomas Hofstaetter 1,000
Melissa A. Kelly Behrs 1,000
Olivia Bloom 1,000
Melissa A. Kelly Behrs 1,000
Olivia Bloom 1,000
Melissa A. Kelly Behrs 1,000
Melissa A. Kelly Behrs 1,000
Olivia Bloom 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 4 4 4 4
Low Target Price Estimate 4 4 4 4
Mean Target Price Estimate 4 4 4 4
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 03/19/18 03/19/18 03/19/18 03/19/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 1 1
Moderate Buy 0 0 0 0
Hold 0 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 0 3 2 2